NCT00002165已完成不适用
Viracept Expanded Access Program
Agouron Pharmaceuticals1 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 1
研究概览
简要总结
To make nelfinavir mesylate (Viracept) available for treatment of HIV positive patients who are unable to take the three commercially available protease inhibitors (because of failure, intolerance, or contraindication) and who have a CD4 cell count of <= 50. To obtain additional information on the safety profile of nelfinavir mesylate (Viracept).
(PER AMENDMENT 1/8/97: People now qualify for the Viracept Program if they are unable to take indinavir and/or ritonavir due to intolerance, contraindication or prior failure.)
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •HIV infection.
- •CD4 T cell count <= 100 cells/mm
- •Failed, been intolerant of or had a contraindication to all three commercially available protease inhibitors (saquinavir, indinavir and ritonavir).
- •(PER AMENDMENT 1/8/97:
- •People now qualify for the Viracept Program if they are unable to take indinavir and/or ritonavir due to intolerance, contraindication or prior failure.)
排除标准
- •Prior Medication:
- •Prior therapy with Viracept.
- •Indinavir.
- •Saquinavir.
- •Ritonavir.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A study to expand access to vemurafenib for patients with BRAFV600 mutation-positive unresectable/recurrent melanoma.melanomaJPRN-UMIN000015572ational Cancer Center Hospital East10
Approved For Marketing
不适用
An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment PossibilitiesLung Diseases, InterstitialNCT03843892Boehringer Ingelheim
已完成
不适用
3TC (Lamivudine; GR109714X) Open-Label ProgramHIV InfectionsNCT00002108Glaxo Wellcome
进行中（未招募）
不适用
GW433908 Expanded Access Program for HIV infected subjects non responding or intolerant to the previous antiretroviral treatmentsHIV infectionMedDRA version: 6.1Level: PTClassification code 10020161EUCTR2004-000336-81-ITGLAXO SMITHKLINE1,500
No Longer Available
不适用
Expanded Access Program With Nivolumab to Treat MelanomaStage III (Unresectable) or Stage IV Advanced MelanomaNCT02142218Bristol-Myers Squibb